The 30-stock Dow lost 44.14 points, or 0.10%, and ended at 42,171.66. The S&P 500 slipped 0.03% to close at 5,980.87, and the ...

This was the stock's second consecutive day of losses.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

GREENVILLE, S.C. (FOX Carolina/AP) - South Carolina is one of 27 states to join a lawsuit to block the sale of 23andMe users’ ...

Kenvue Inc.'s stock had its worst day in nearly two years on Tuesday, as the maker of Band-Aids, Benadryl and Tylenol said tariffs, persistent inflation and weaker demand for allergy medicine, due to ...

Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease ...

This mixed outcome, combined with unmet high expectations for the drug’s performance, triggered a sharp sell-off ... looking for an AI stock that is more promising than REGN and that has ...

Wall Street analysts issued a fresh round of ratings changes on Friday, including notable downgrades for Airbnb (ABNB), Regeneron (REGN), and Cooper Companies (COO), and upgrades for Unity (U) and ...

Price Action: REGN stock is down 9.98% at $545, and SNY stock is down 4.57% at $49.96 during the premarket session at last check Friday.

U.S. equities were mixed at midday, with the market following the progress of the Republican tax cut and spending bill that could be heading to a vote soon.

Representative Robert Bresnahan Jr. made waves by selling shares in Regeneron Pharmaceuticals ... What’s certain, though, is that this pharmaceutical sell-off has put a spotlight on his portfolio ...